Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Maria Vidal Losada

17PUBLICATIONS

117CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersEnvironmental epidemiologyMolecular targetsTumour immunology

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (17)

Sort by Publication Date:

|Feb 16, 2026

Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).

Tomás Pascual, Maria Vidal, Juan M Cejalvo

|Jan 22, 2026

Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes.

Benedetta Conte, Fara Brasó-Maristany, Tomás Pascual

|Oct 08, 2025

Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.

Shanu Modi, William Jacot, Hiroji Iwata

|Feb 08, 2025

Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study.

Regina Peña-Enríquez, Begoña Bermejo, Marina Pollán

|Jan 17, 2025

Elacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial.

Maria Vidal, Claudette Falato, Tomás Pascual

|Oct 08, 2024

A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study.

Patrick Neven, Nicole Stahl, Maria Vidal

Pageof 3

Frequent Collaborators

12 joint publications

Aleix Prat

11 joint publications

Tomás Pascual

5 joint publications

Mafalda Oliveira

5 joint publications

Eva Ciruelos

5 joint publications

Fara Brasó-Maristany

4 joint publications

Juan Manuel Ferrero-Cafiero

3 joint publications

Laia Paré

2 joint publications

Gaia Griguolo

2 joint publications

María Teresa Martínez Martínez

2 joint publications

Silvia Antolín Novoa

Frequent Collaborators

12 joint publications

Aleix Prat

11 joint publications

Tomás Pascual

5 joint publications

Mafalda Oliveira

5 joint publications

Eva Ciruelos

Top Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on : Jul 25, 2020

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on : Dec 05, 2017

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on : Apr 26, 2024

See more related videos

Top Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on : Jul 25, 2020

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on : Dec 05, 2017

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on : Apr 26, 2024

See more related videos